Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 6/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ACLY | P53396 | 2/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24435805 | 0.83 | MCL1 (0.60) | CCR2CA1CA2TSHRHPGD | |
| SCHEMBL12601590 | 0.83 | LMNA (0.51) | CCR2CA1CA2TSHRLMNA | |
| SCHEMBL905181 | 0.81 | CCR2 (0.54) | CCR2TSHRTAS2R14KMT2A | |
| SCHEMBL19303541 | 0.78 | PSIP1 (0.59) | CCR2TSHRTAS2R14LMNAKMT2A | |
| SCHEMBL31046878 | 0.78 | SLC22A12 (0.59) | CCR2TSHRACLYKMT2AHPGD | |
| SCHEMBL23141320 | 0.78 | SLC22A12 (0.59) | CCR2TSHRACLYKMT2AHPGD | |
| SCHEMBL19997238 | 0.77 | KMT2A (0.51) | CCR2CA1CA2TSHRLMNA | |
| SCHEMBL23877540 | 0.76 | ACLY (0.61) | ACLY | |
| SCHEMBL27183177 | 0.76 | CA1 (0.47) | CCR2CA1CA2TSHRTAS2R14 | |
| SCHEMBL14830771 | 0.75 | PSIP1 (0.59) | CA1CA2TSHRACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091472-B2 | PI-kinase inhibitors with anti-infective activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-17 | — | — | US | disclosed |
| US-9926309-B2 | Pi-kinase inhibitors with anti-infective activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091472-B2 | PI-kinase inhibitors with anti-infective activity | PIP4K2A, PIP5K1A, PIP4K2C | CCR2 3995/4885CA1 4838/4885CA2 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.